论文部分内容阅读
目的探讨端粒酶活性在肺癌患者诱导痰中表达的临床意义。方法采用TRAP-PCR-ELISA法对30例肺癌患者诱导痰、自然痰及15例肺部良性病变者诱导痰中端粒酶活性进行测定。结果肺癌患者的诱导痰、自然痰以及非肺癌患者诱导痰中的端粒酶阳性率分别为80.0%、56.7%、13.3%;OD值分别为(0.52±0.27)、(0.35±0.25)、(0.09±0.11)。肺癌诱导痰组端粒酶的阳性率及OD值均高于自然痰组及良性对照组,差异有显著性意义(P<0.01)。10例小细胞肺癌(SCLC)化疗后诱导痰中端粒酶OD值明显下降,与化疗前比较差异有显著性意义(P<0.01)。结论诱导痰中端粒酶活性的检测有助于肺癌的诊治及其与肺部良性疾病的鉴别诊断,且优于自然痰。
Objective To investigate the clinical significance of telomerase activity in induced sputum in patients with lung cancer. Methods TRAP-PCR-ELISA was used to detect the telomerase activity in sputum from 30 cases of lung cancer induced sputum, natural sputum and 15 cases of lung benign lesions. Results The positive rates of telomerase in induced sputum, natural sputum and sputum in patients with lung cancer were 80.0%, 56.7% and 13.3%, respectively; the OD values were (0.52 ± 0.27), (0.35 ± 0.25), 0.09 ± 0.11). The positive rate and OD value of telomerase in lung cancer induced sputum group were higher than those in natural sputum group and benign control group, the difference was significant (P <0.01). The OD value of telomerase in induced sputum of 10 patients with SCLC was significantly lower than that before chemotherapy (P <0.01). Conclusion The detection of telomerase activity in induced sputum is helpful for the diagnosis and treatment of lung cancer and its differential diagnosis with benign lung diseases, and is superior to natural sputum.